生物瓦克斯宣布修订后的生命提供方案-动脉网

BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING

CISION 等信源发布 2025-06-20 14:21



可切换为仅中文







// NOT FOR DISTRIBUTION TO

// 不用于分发给

UNITED STATES

美国

NEWSWIRE SERVICES OR FOR DISSEMINATION IN

新闻专线服务或用于传播

THE UNITED STATES

美国

VANCOUVER, BC

加拿大温哥华

，

June 20, 2025

2025年6月20日

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ('

/PRNewswire/ -- BioVaxys技术公司（CSE: BIOV）（FRA: 5LB）（

BioVaxys

百欧维希斯

' or the '

‘ 或者 ‘

Company

公司

') announces that it has amended the terms of its brokered private placement LIFE financing (the '

“）宣布其已修改了由经纪商进行的私募 LIFE 融资的条款（”

Offering

提供

') previously announced on

`) 之前宣布的于`

May 30, 2025

2025年5月30日

, and filed an amended offering document (the '

，并提交了修订后的招股文件（“

Amended Offering Document

修订后的招股说明书

'). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units ('

`).修订后的招股文件更新了作为单位组成部分的普通股购买权证的行使价（`

Units

单位

') being offered by the Company from a post-consolidation exercise price of

`) 公司在合并后的行权价为`

$0.60

0.60美元

to a post-consolidation exercise price of

整合后的行权价格为

$0.50

0.50美元

。

As previously announced, the Company intends to consolidate the common shares of the Company (the '

正如之前宣布的，公司打算合并公司的普通股（“

Common Shares

普通股

') on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the '

`) 以前十股（10）合一股（1）的基准进行合并（即`

Consolidation

整合

'), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of

"），并完成一项同时进行的发行，该发行至少包括5,714,285个单位，合并后的价格为"

$0.35

0.35美元

per Unit for minimum gross proceeds of

每单位最低毛收入为

$2,000,000

2000000美元

and a maximum of 8,571,428 Units at a post-Consolidation price of

最多8,571,428股，合并后价格为

$0.35

0.35美元

per Unit for maximum gross proceeds of up to

每单位最高总收益可达

$3,000,000

3,000,000美元

。

Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a '

每个单位将由公司资本中的一股（1）合并后的普通股组成（每一股称为一个“

Post-Consolidation Common Share

合并后普通股

') and one (1) Post-Consolidation Common Share purchase warrant (each, a '

`) 以及一股（1）合并后普通股购买权证（每个，一 `

Post-Consolidation Warrant

合并后认股权证

'). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of

`). 每张合并后认股权证将使持有人有权以合并后的价格购买一股合并后普通股，价格为`

$0.50

0.50美元

for a period of 36 months from the closing date of the Offering.

自本次发售结束之日起的36个月内。

Closing of the Offering is anticipated to occur on or about

预计发售的完成将在或约在

June 30, 2025

2025年6月30日

, or such other date as the Company may agree upon provided such date is on or before

，或公司可能同意的其他日期，前提是该日期在或之前

July 14, 2025

2025年7月14日

. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital.

本次发行的完成取决于满足某些条件，包括但不限于CSE的批准。公司计划将从本次发行中筹集的净收益用于研究与开发、一般公司用途及营运资金。

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 –

在遵守适用的监管要求的前提下，并根据国家文书45-106号——

Prospectus Exemptions

招股说明书豁免

NI 45-106

'), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of

“），根据发行可发行的单位将向所有省和地区的购买者出售。”

Canada

加拿大

, except

，除了

Quebec

魁北克

, pursuant to the listed issuer financing exemption ('

，根据上市发行人融资豁免（

LIFE

生命

') under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws.

根据《NI 45-106》第5A部分的“')”。根据适用的加拿大证券法，此次发行中销售单位所涉及的证券将不受转售限制。

There is an Amended Offering Document dated

有一份修订后的发行文件，日期为

June 18, 2025

2025年6月18日

, related to the Offering that can be accessed under the Company's profile at

，与发行相关的内容可以在公司概况下的以下位置访问：

www.sedarplus.ca

and on the Company's website at

并在公司的网站上

https://www.biovaxys.com/

. Prospective investors should read this offering document before making an investment decision.

潜在投资者在做出投资决定之前应阅读本招股文件。

This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in

本新闻稿不构成出售或购买任何证券的要约或要约邀请。

the United States

美国

, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the '

，或在任何此类要约、招揽或销售属违法的司法管辖区。本文所述证券尚未根据1933年修订的《美国证券法》（“

U.S. Securities Act

美国证券法

'), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom.

“），或任何州证券法，并且除非符合美国证券法和适用的州证券法的注册要求，或根据可用的豁免条款，不得在美国境内提供或出售。”

About BioVaxys Technology Corp.

关于BioVaxys技术公司

BioVaxys Technology Corp. (

BioVaxys技术公司 (

www.biovaxys.com

), a biopharmaceuticals company registered in

），一家注册于

British Columbia, Canada

加拿大不列颠哥伦比亚省

, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases.

是一家临床阶段的生物制药公司，致力于通过基于DPX™免疫教育技术平台及其HapTenix©肿瘤细胞构建平台的新型免疫疗法，改善癌症、传染病、食物过敏抗原脱敏及其他免疫疾病患者的生活。

Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer.

通过差异化的作用机制，DPX™ 平台向免疫系统发出指令，以生成特定、强大且持久的免疫反应。公司处于临床阶段的产品线包括基于 DPX™ 平台的马维罗肽-S（MVP-S），该产品正在进行针对晚期复发-难治性弥漫性大B细胞淋巴瘤（DLBCL）和铂类耐药卵巢癌的 II 期临床开发。

MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response.

MVP-S递送来自survivin的抗原肽，survivin是一种在晚期癌症中普遍过表达的公认的癌症抗原，同时递送一种先天免疫激活剂和一种通用的CD4 T细胞辅助肽。MVP-S在多种癌症适应症中表现出良好的耐受性，并显示出明确的临床益处，还激活了针对性且持久的survivin特异性抗肿瘤免疫反应。

BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer..

BioVaxys 还在开发 DPX™+SurMAGE，这是一种双重靶向免疫疗法，结合了针对 survivin 和 MAGE-A9 癌蛋白的抗原肽，以同时引发对这两种不同癌抗原的免疫反应；DPX™-RSV 用于呼吸道合胞病毒；DPX+rPA 用于花生过敏预防；以及 BVX-0918，一种个性化的免疫治疗疫苗，利用其专有的 HapTenix© “新抗原”肿瘤细胞构建平台，针对难治性晚期卵巢癌。

BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV' and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit

BioVaxys普通股在CSE上市，股票代码为'BIOV'，并在法兰克福证券交易所（FRA：5LB）和美国OTC市场（OTCQB市场）交易。欲了解更多信息，请访问。

www.biovaxys.com

and connect with us on X and LinkedIn.

并在X和LinkedIn上与我们联系。

ON BEHALF OF THE BOARD

代表董事会

Signed '

已签名 '

James Passin

詹姆斯·帕辛

James Passin, Chief Executive Officer

詹姆斯·帕辛，首席执行官

Phone: +1 740 358 0555

电话：+1 740 358 0555

Cautionary Statements on Forward Looking Information

前瞻性信息的警示声明

This news release includes certain 'forward-looking information' and 'forward-looking statements' (collectively '

本新闻稿包含某些“前瞻性信息”和“前瞻性陈述”（统称为“

forward-looking statements

前瞻性声明

') within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'potential', 'possible', and similar expressions, or statements that events, conditions, or results 'will', 'may', 'could', or 'should' occur or be achieved.

“）根据适用证券法规的含义。所有陈述，除历史事实陈述外，均包含在本文中，包括但不限于与公司未来经营或财务业绩相关的陈述，均为前瞻性陈述。前瞻性陈述经常但并非总是通过诸如“预期”、“预计”、“相信”、“打算”、“估计”、“潜在”、“可能”，以及类似表述或事件、条件或结果“将”、“可能”、“能够”或“应该”发生或实现的陈述来识别。”

Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE.

本新闻稿中的前瞻性陈述涉及以下事项：拟议的合并，包括其比例和时间安排，以及发行，包括发行规模、所得款项用途、时间安排，以及公司完成发行的能力，包括获得CSE对发行的批准。

There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. .

无法保证这些陈述的准确性，实际结果和未来事件可能与这些前瞻性陈述中表达或暗示的内容有重大差异。

Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals.

前瞻性声明反映了声明作出时的信念、意见和预测，基于若干假设和估计，主要是假设BioVaxys将成功开发和测试疫苗。尽管BioVaxys认为这些假设是合理的，但它们本质上受到重大的商业、经济、竞争、政治和社会不确定性和偶然性的影响，主要包括但不限于BioVaxys疫苗可能证明无效和/或无法获得所需的监管批准的风险。

With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties..

关于BioVaxys的业务，有许多风险可能会影响其生物技术产品的开发，包括但不限于：为临床试验提供资金所需的额外资本、缺乏运营历史、其产品是否能够完成漫长、复杂且昂贵的临床试验和监管审批流程以获得新药上市批准的不确定性、其自体细胞疫苗免疫疗法是否能够开发出安全有效的产品以及如果能够开发出来，其疫苗产品是否会被市场接受并盈利的不确定性、开发阶段生物制药企业通常遇到的费用、延迟、不确定性和复杂性、为保护其产品和技术权利而需履行的财务和开发义务、获取和保护新的知识产权以及避免侵犯第三方权益，还有对第三方制造的依赖。

Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors.

许多已知和未知的因素可能导致实际结果、业绩或成就与这些前瞻性陈述中表达或暗示的结果、业绩或成就存在重大差异，且各方已基于或关联这些因素中的许多内容作出了假设和估计。

Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws..

这些因素包括但不限于公司能否按提议的条款或完全完成合并和发行，以及能否获得必要的批准，包括CSE的批准。BioVaxys不承担更新前瞻性陈述的义务，即使信念、意见、预测或其他因素发生变化，除非适用的证券法要求。

The CSE has not reviewed, approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this news release.

加拿大证券交易所（CSE）尚未审查、批准或不批准本新闻稿的内容，也不对本新闻稿的充分性或准确性承担责任。

Logo:

标志：

https://mma.prnewswire.com/media/1430981/5379811/BIOVAXYS_Logo.jpg

SOURCE BioVaxys Technology Corp.

来源：BioVaxys技术公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+